Fortacin

RSS

lidocaine / prilocaine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Fortacin. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Fortacin.

For practical information about using Fortacin, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 19/09/2018

Authorisation details

Product details
Name
Fortacin
Agency product number
EMEA/H/C/002693
Active substance
  • lidocaine
  • prilocaine
International non-proprietary name (INN) or common name
lidocaine / prilocaine
Therapeutic area (MeSH)
Sexual Dysfunction, Physiological
Anatomical therapeutic chemical (ATC) code
N01BB20
Publication details
Marketing-authorisation holder
Plethora Solutions Limited
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
15/11/2013
Contact address
Recordati Ireland Ltd.
Raheens East
Ringaskiddy, Co. Cork,
Ireland

Product information

17/09/2018 Fortacin - EMEA/H/C/002693 - R/0023

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ANESTHETICS

Therapeutic indication

Treatment of primary premature ejaculation in adult men.

Assessment history

How useful was this page?

Add your rating
Average
1 rating